Greg Hoyt featured in an editorial article by Biocompare, “Perspectives on Pilot Plants”

Greg Hoyt featured in an editorial article by Biocompare, “Perspectives on Pilot Plants”

Mar 11, 2019

Pilot plants represent a milestone in a drug’s commercial development, where drug sponsors first explore engineering, commercialization, clinical, regulatory, and process issues outside the relative safety of laboratory scale. And, as the test ground for a product’s ultimate manufacturability, pilot scale is where drug sponsors often return to de-bottleneck or to solve unanticipated production issues.

Traditionally, companies build pilot plants before they know if a drug will be approved. This uncertainty underpins critical decision-making on both pilot and manufacturing-scale capacity, the introduction of novel manufacturing technologies, implementing scaleup and scaledown strategies, and how to conduct knowledge and process technology transfer.

Read the full story here: https://www.biocompare.com/Editorial-Articles/358606-Perspectives-on-Pilot-Plants/ 

 

Greg Hoyt Article CRBnet